D
David D. Waters
Researcher at University of California, San Francisco
Publications - 28
Citations - 19159
David D. Waters is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Myocardial infarction & Atorvastatin. The author has an hindex of 23, co-authored 28 publications receiving 17742 citations. Previous affiliations of David D. Waters include University of California, Los Angeles & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
John C. LaRosa,Scott M. Grundy,David D. Waters,Charles L. Shear,Philip J. Barter,Jean Charles Fruchart,Antonio M. Gotto,Heiner Greten,John J.P. Kastelein,James Shepherd,Nanette K. Wenger +10 more
TL;DR: Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of least-in- LDL cholesterol levels per day, with a greater incidence of elevated aminotransferase levels.
Journal ArticleDOI
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter,Mark J. Caulfield,Mats Eriksson,Scott M. Grundy,John J.P. Kastelein,Michel Komajda,Jose Lopez-Sendon,Lori Mosca,Jean-Claude Tardif,David D. Waters,Charles L. Shear,James H. Revkin,Kevin A. Buhr,Marian R. Fisher,Alan R. Tall,Bryan Brewer +15 more
TL;DR: Although there was evidence of an off-target effect of torcetrapib, it cannot rule out adverse effects related to CETP inhibition, and the trial was terminated prematurely because of an increased risk of death and cardiac events.
Journal ArticleDOI
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Gregory G. Schwartz,Anders G. Olsson,Michael D. Ezekowitz,Peter Ganz,Michael F. Oliver,David D. Waters,Andreas M. Zeiher,Bernard R. Chaitman,S. Leslie,Theresa Stern +9 more
TL;DR: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes and the MIRACL study are studied.
Journal ArticleDOI
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif,Simon Kouz,David D. Waters,Olivier F. Bertrand,Rafael Diaz,Aldo P. Maggioni,Fausto J. Pinto,Reda Ibrahim,Habib Gamra,Ghassan S. Kiwan,Colin Berry,José López-Sendón,Petr Ostadal,Wolfgang Koenig,Denis Angoulvant,Jean Grégoire,Marc-André Lavoie,Marie-Pierre Dubé,David Rhainds,Mylène Provencher,Lucie Blondeau,Andreas Orfanos,Philippe L. L’Allier,Marie-Claude Guertin,François Roubille +24 more
TL;DR: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.
Journal ArticleDOI
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss,Sreenivasa Rao Kondapally Seshasai,Paul Welsh,Sabina A. Murphy,Jennifer E. Ho,David D. Waters,David A. DeMicco,Philip J. Barter,Christopher P. Cannon,Marc S. Sabatine,Eugene Braunwald,John J.P. Kastelein,James A. de Lemos,Michael A. Blazing,Terje R. Pedersen,Matti J. Tikkanen,Naveed Sattar,Kausik K. Ray +17 more
TL;DR: In this paper, the authors investigated whether intensive-dose statin therapy is associated with increased risk of new-onset diabetes compared with moderate-dose stochastic insulin this paper.